Professor Gerrit Frommeyer
University Hospital of Munster, Munster (Germany)
Safe electrophysiologic profile of the neprilysin-inhibitor sacubitril in combination with different antiarrhythmic drugs
Event: ESC Congress 2022
Topic: Drug Treatment of Ventricular Arrhythmias
Session: Pharmacological and metabolic impact on ventricular arrhythmias
Divergent electrophysiologic safety profile of dapagliflozin and empagliflozin in a whole-heart model
Event: ESC Congress 2022
Topic: Arrhythmias
Session: Mechanisms of atrial and ventricular arrhythmias
Dapagliflozin but not empagliflozin prevents atrial fibrillation in an experimental whole-heart model
Event: ESC Congress 2022
Topic: Cellular Electrophysiology
Session: Insights into arrhythmia mechanisms
Beneficial electrophysiologic effects of sacubitril in different arrhythmia syndromes
Event: ESC Congress 2020
Topic: Pathophysiology and Mechanisms
Session: Arrhythmias, General ePosters
Dexmedetomidine reduces ventricular arrhythmias in a model of drug-induced QT-prolongation
Event: ESC Congress 2020
Topic: Antiarrhythmic Drug Treatment
Session: Arrhythmias, General ePosters
Arrhythmogenic effects of non-steroidal anti-inflammatory drugs (NSAID)
Event: ESC Congress 2019
Topic: Risk Factors and Risk Assessment
Session: Basic Science
Time-to-isolation-guided cryoballoon pulmonary vein isolation reduces esophageal and mediastinal alterations detected by endoscopic ultrasound
Event: ESC Congress 2019
Topic: Rhythm Control, Catheter Ablation
Session: New insights in atrial fibrillation ablation: techniques and complications
Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy - data from the German device Registry
Event: ESC Congress 2019
Topic: Implantable Cardioverter-Defibrillator (ICD)
Session: Arrhythmia in cardiomyopathy
Long-term single-center experience of transvenous defibrillator therapy in children and adolescents
Event: ESC Congress 2018
Topic: Implantable Cardioverter-Defibrillator (ICD)
Session: Implantable cardioverter defibrillation : treatment outcomes
Ranolazine reduces levosimendan-mediated atrial fibrillation in an experimental whole-heart model
Event: ESC Congress 2018
Topic: Antiarrhythmic Drug Treatment
Session: Arrhythmia mechanisms - General
ESC 365 is supported by
